open access

Vol 48, No 1 (2010)
Original paper
Published online: 2010-06-10
Submitted: 2011-12-19
Get Citation

Targeting novel antigens in the arterial wall in thromboangiitis obliterans.

Elif Guzel, Ender Topal, Ayse Yildirim, Pergin Atilla, Murat Akkus, Attila Dagdeviren
DOI: 10.2478/v10042-008-0104-6
·
Folia Histochem Cytobiol 2010;48(1):134-141.

open access

Vol 48, No 1 (2010)
ORIGINAL PAPERS
Published online: 2010-06-10
Submitted: 2011-12-19

Abstract

Thromboangiitis obliterans is an inflammatory disease possibly resulting from cigarette smoking as a primary etiologic factor, perhaps as a delayed type of hypersensitivity or toxic angiitis. As little is known about the pathogenesis of the disease, we aimed to determine novel antigens that might be responsible from the local inflammatory reactions and structural changes observed in this disease. An indirect immunoperoxidase technique is used to examine the tissue samples obtained from the dorsalis pedis artery of affected individuals with twenty monoclonal antibodies. Among these several antigens which are not previously reported in TAO like CD34, CD44 and CD90 were determined in the tissue samples examined. On the other hand, many other antigens like cytokine/chemokine receptors, several enzymes and leukocyte/lymphocyte antigens were lacking giving some clues about the local pathological reactions. We briefly discussed our findings for several critical antigens those first described in the present work, possibly having roles in the development of the disease. Expression of the CD90/CD11c receptor/ligand pair seems to play an important role in mononuclear cell recruitment to the damage site. Vascular invasion of not only tunica intima but also the tunica media in affected vessels is clearly demonstrated using endothelial cell specific antigens.

Abstract

Thromboangiitis obliterans is an inflammatory disease possibly resulting from cigarette smoking as a primary etiologic factor, perhaps as a delayed type of hypersensitivity or toxic angiitis. As little is known about the pathogenesis of the disease, we aimed to determine novel antigens that might be responsible from the local inflammatory reactions and structural changes observed in this disease. An indirect immunoperoxidase technique is used to examine the tissue samples obtained from the dorsalis pedis artery of affected individuals with twenty monoclonal antibodies. Among these several antigens which are not previously reported in TAO like CD34, CD44 and CD90 were determined in the tissue samples examined. On the other hand, many other antigens like cytokine/chemokine receptors, several enzymes and leukocyte/lymphocyte antigens were lacking giving some clues about the local pathological reactions. We briefly discussed our findings for several critical antigens those first described in the present work, possibly having roles in the development of the disease. Expression of the CD90/CD11c receptor/ligand pair seems to play an important role in mononuclear cell recruitment to the damage site. Vascular invasion of not only tunica intima but also the tunica media in affected vessels is clearly demonstrated using endothelial cell specific antigens.
Get Citation
About this article
Title

Targeting novel antigens in the arterial wall in thromboangiitis obliterans.

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 48, No 1 (2010)

Article type

Original paper

Pages

134-141

Published online

2010-06-10

DOI

10.2478/v10042-008-0104-6

Bibliographic record

Folia Histochem Cytobiol 2010;48(1):134-141.

Authors

Elif Guzel
Ender Topal
Ayse Yildirim
Pergin Atilla
Murat Akkus
Attila Dagdeviren

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl